Charcot-Marie-Tooth disease type 4 C (CMT4C) is an autosomal recessive form of demyelinating peripheral neuropathy caused by mutations in SH3TC2, characterized by early onset, spine deformities, and cranial nerve involvement. We screened SH3TC2 in 50 unrelated Greek patients with suspected demyelinating Charcot-Marie-Tooth disease and pedigree compatible with recessive inheritance. All patients had been previously screened for PMP22, GJB1, and MPZ mutations. We found five previously identified pathogenic mutations in SH3TC2 distributed among 13 patients in homozygosity or compound heterozygosity (p. Arg954Stop, Arg1109Stop, Gln892Stop, Ala878Asp, and Arg648Trp). Although most cases had early onset and spine deformities were almost omnipresent, a wide phenotypic spectrum was observed.
| INTRODUCTION
Charcot-Marie-Tooth type 4 C (CMT4C) is one of the most frequent autosomal recessive forms of hereditary demyelinating peripheral neuropathy. 1, 2 It is characterized by early onset, usually in the first decade of life, spine, and foot deformities and cranial nerve abnormalities, with severity usually ranging from moderate to disabling. Overall, it is a slowly progressive neuropathy that can occasionally lead to loss of ambulation. CMT4C is caused by homozygous or compound heterozygous mutations in the SH3 domain tetratricopeptide repeats 2 gene (SH3TC2). 3 The encoded protein is strongly expressed in neural tissues and seems to participate in the endocytic pathway as per its localization in the plasma membrane. 4 Loss of functional SH3TC2 protein leads to Schwann cell and node of Ranvier alterations. Specifically, wider nodes of Ranvier and unusually thin myelin sheaths are observed. 5, 6 As a consequence, conduction velocities (CVs) lie within the demyelinating range (median nerve motor CV < 38 m/s). Numerous other pathogenic mutations are also located in exon 11, which is the largest exon, indicating a possible mutational hotspot. 3, 8 Herein, we report the clinical, electrophysiological, and molecular findings of Greek patients with CMT4C identified by mutational screening, drawing attention to the varied phenotypic spectrum and unusual clinical features of particular interest.
Georgia Karadima and Georgios Koutsis contributed equally to this study. regions of the country. All 88 originally selected patients were initially screened for PMP22, GJB1, and MPZ mutations, and only negative patients further studied (see patient flow diagram in Figure 1 ).
| PATIENTS AND METHODS
All 50 index patients were first screened for the p. Arg954Stop mutation using polymerase chain reaction (PCR) and restriction-fragment-length-polymorphisms . We then proceeded to Sanger sequencing of SH3TC2 exons 10, 11, 12, 14, and 16 according to previously established procedures. 3 The PCR product was purified and then sequenced in both directions using Big Dye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, California). Sequences were analyzed using Sequencher 5.1 (Gene Codes Corporation, Ann Arbor, MI). Variants found are described with reference to the SH3TC2 transcript NM_000166.5. In addition to the index patients identified with CMT4C, limited data were collected on affected relatives.
All patients or their guardians gave written informed consent for the performance of molecular genetic testing and inclusion in this study, which was approved by the Eginition Hospital ethics committee.
3 | RESULTS
| Genetic findings
SH3TC2 mutations were found in 13 out of 50 index cases screened (26%). In recessive families, 3 out of 6 were positive (50%), and in isolated cases 10 out of 44 (23%), as shown in Figure 1 . In total, five previously identified pathogenic mutations were identified ( Figure 2 ). Among these, only Arg954Stop was found in homozygosity in 6 out of 13 cases.
The remaining seven cases were compound heterozygous with the Arg954Stop mutation in cis. Of these, 4 out of 7 had the Arg1109Stop mutation (exon 14) in trans and each of the rest a different exon 11 mutation in trans (Gln892Stop, Ala878Asp, and Arg648Trp). Table 1 displays demographic and clinical findings of 13 index patients with CMT4C, with limited data from four affected relatives. All patients had onset in infancy or childhood, excepting one case who reported no symptoms till age 55 years (patient 9). The presenting symptom in all cases was gait disturbance. Overall, a wide spectrum of disease severity was observed ranging from mild weakness and sensory loss to severe weakness and sensory loss with loss of ambulation (patients 13 and 17).
| Clinical findings and electrophysiology
Scoliosis was virtually omnipresent, although its severity did not necessarily correspond to the severity of the neuropathy (patients 4 and 5).
Cranial nerve involvement was a characteristic finding, present in four index patients (31%). The acoustic nerve was most commonly involved (patients 5 and 13), followed by the trigeminal (patient 4), facial (patient 7), vagus (patient 13), and hypoglossal (patient 7). Brain magnetic resonance imaging (MRI) in these patients was unremarkable. The presence of carbamazepine-responsive trigeminal neuralgia in patient 4 at the age of 27 years with unremarkable brain MRI is particularly noteworthy. We also note the presence of mild head tremor in patient 13.
The most notable phenotype identified in our cohort was RoussyLévy syndrome in two affected siblings of family 10 ( In accordance with the literature, Arg954Stop was the most frequent SH3TC2 mutation found in all 13 cases (73.0% of mutated alleles), followed by Arg1109Stop found in four cases (15.4% of mutated alleles). The frequency of these mutations appears similar to reports from Italian, French, Dutch, and Czech cohorts, classifying
Greek CMT patients among populations with the highest percentage. 1,6,9,10 Mutation Arg954Stop in homozygosity or compound heterozygosity has been strongly linked in one large study to an early onset mild-to-moderate neuropathy. 1 However, a greater variability in disease severity has been reported with this mutation in other cohorts, a finding corroborated by our data, which included severely affected patients. 3, 5, 6, 8, 9 Mutation Arg1109Stop has been reported as particularly frequent in Gypsies with a likely founder effect. 11, 12 However, it has also been identified in Italian and Albanian patients without known Gypsy ancestry. 11 Interestingly, none of our patients with the mutation had any known Gypsy ancestry.
Mutation Gln892Stop has been previously reported in CMT4C
cohorts form France and Italy in homozygosity or compound hererozygosity with Arg954Stop. 9, 10 Patients from the Italian study with this mutation were all from the same region in Albania, suggesting a possible founder effect. There was no evidence of Albanian origin in our patient. proprioceptive ataxia in patients with CMT4C has been previously noted, and it has been recently suggested that this may be a prominent feature of the disease. 8, 9, 11, 14 However, no patients specifically diagnosed as Roussy-Lévy syndrome and initially investigated as suspected Friedreich's ataxia has been previously reported. It has however been noted that sensory ataxia can be severe leading to difficulty standing without support. 9 The actual diagnosis of Roussy-Lévy syndrome draws further attention to the ataxic phenotype of CMT4C, as a rare but prominent clinical variant.
The second particularly notable clinical feature was young-onset trigeminal neuralgia. This has been previously reported in an Italian patient with CMT4C due to homozygous Arg1109Stop mutations, but, possibly because of his older age (55 years), particular attention was not drawn to the observation. 9 Trigeminal neuralgia has only very rarely been reported in CMT, suggesting it may be a characteristic, albeit rare feature of CMT4C. Further findings of interest that have only rarely been reported include facial paresis, vocal cord involvement, hypoglossal involvement, and head tremor. 10, 11, 17 Head tremor in particular has been previously observed in a single patient with severe neuropathy and multiple cranial nerve abnormalities examined in his 40s, features present in our patient too, who was also examined in her 40s. 11 The above findings complete the varied phenotypic spectrum associated with SH3TC2 mutations observed in the present cohort.
All our patients had clear electrophysiological evidence of a diffuse, homogeneous sensorimotor demyelinating neuropathy with variable axonal loss, more severe in the lower limbs. This is in accordance with previous studies. [9] [10] [11] 17 The absence of sensory action potentials in >90% of lower limb and approximately 70% of upper limb recordings reflects the severity of sensory involvement that can lead to severe sensory ataxia and the Roussy-Lévy phenotype in extreme cases.
Our study is limited by the fact that only 5 out of 17 exons of SH3TC2 were sequenced. It is, therefore, possible that further unidentified mutations in this gene are present in our CMT4 cohort. This may have led to an underestimation of the overall frequency of CMT4C. However, it is noteworthy that the five exons sequenced cover >50% of the whole coding sequence and include previously described mutation hotspots. 17 It is therefore unlikely that the CMT4C landscape in the Greek population would be substantially different were the gene fully sequenced.
In conclusion, mutations in SH3TC2 account for 26% of all CMT4 cases in the Greek population. The Arg954Stop mutation, in particular, appears universally present in hemizygous or homozygous state.
Accordingly, we have incorporated in our diagnostic practice a targeted PCR for Arg954Stop as the second diagnostic step (following exclusion of the PMP22 duplication) in the molecular investigation of suspected CMT4, before moving on to more costly testing. 
